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ABSTRACT
Despite initial responsiveness to both chemotherapy and radiotherapy, small 
cell lung cancer (SCLC) commonly relapses within months. Although neuroendocrine 
characteristics may be difficult to demonstrate in individual cases, a relevant 
expression of somatostatin receptors (SSTR) on the cell surface has been described. 
We aimed to evaluate the prognostic value of SSTR-expression in advanced SCLC. We 
further examined pre-requisites for successful peptide receptor radionuclide therapy 
(PRRT).
21 patients with extensive stage SCLC were enrolled. All patients underwent 
positron emission tomography/computed tomography (PET/CT) with 68Ga-DOTATATE 
to select patients for SSTR-directed therapy. PET scans were visually and semi-
quantitatively assessed and compared to SSTR2a and SSTR5 expression in biopsy 
samples. Peak standardized uptake values (SUVpeak) of tumors as well as tumor-to-
liver ratios were correlated to progression-free (PFS) and overall survival (OS).
In 4/21 patients all SCLC lesions were PET-positive. 6/21 subjects were rated 
“intermediate” with the majority of lesions positive, the remaining 11/21 patients 
were PET-negative. PET-positivity correlated well with histologic SSTR2a, but not 
with SSTR5 expression. Neither PET-positivity nor SUVpeak were predictors of PFS or 
OS. In 4 patients with intensive SSTR2a-receptor expression, PRRT was performed 
with one partial response and one stable disease, respectively.
SSTR-expression as detected by 68Ga-DOTATATE-PET and/or histology is not 
predictive of PFS or OS in patients with advanced SCLC. However, in patients exhibiting 
sufficient tracer uptake, PRRT might be a treatment option given its low toxicity and 
the absence of effective alternatives.
INTRODUCTION
Small cell lung cancer (SCLC) represents 15% of 
all lung cancers and occurs predominantly in smokers [1]
Due to its rapid doubling time, high growth fraction, 
and the early development of metastases, only one-third of 
patients are diagnosed with localized disease [2]. Although 
SCLC is highly responsive to both chemotherapy and 
radiotherapy, it commonly relapses within months despite 
treatment [3, 4].
SCLC represents the most aggressive member of 
a family of tumors with neuroendocrine features such as 
typical and atypical carcinoids or large cell neuroendocrine 
carcinomas (LCNEC). Although neuroendocrine 
characteristics may be difficult to demonstrate in 
individual cases, a relevant expression of somatostatin 
receptors (SSTR) on the cell surface has been described 
[5, 6].
The 68Ga/177Lu/90Y-labelled compound DOTATATE/-
TOC has been shown to reliably and selectively bind to 
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SSTR2a (and SSTR5). It is widely used in imaging (68Ga) 
and therapy (177Lu, 90Y) of neuroendocrine tumors [7, 8]. 
The aim of this study was to evaluate the prognostic value 
of SSTR-expression in patients with advanced SCLC. 
We further examined pre-requisites for successful peptide 
receptor radionuclide therapy (PRRT) in this patient group.
RESULTS
Patients
At the time of SSTR-PET/CT, all patients 
presented with extensive disease and suffered from 
tumor progression. Metastatic sites included lymph nodes 
(19/21), liver (10/21), bone (10/21), adrenals (8/21), lung 
(5/21), brain (4/21), pleura (4/21), pancreas (1/21) and 
skin (1/21). During follow-up, all patients deceased with 
20/21 dying from SCLC and 1 subject from pneumonia. 
Median PFS was 70 days (range, 2-766 d), median OS 118 
days (range, 3-907 d).
SSTR-PET/CT-Imaging
On visual analysis, 4/21 patients were rated 
“positive” with all SCLC lesions displaying higher 
tracer uptake than liver parenchyma, 6/21 were 
rated “intermediate”, and 11/21 presented with 68Ga-
DOTATATE-negative disease (Figure 1). The SUVpeak 
values and the T/L ratios of the maximum tumor to mean 
liver SUV are listed in Table 1. Both SUVpeak values 
(p<0.001, Kruskal-Wallis test) and T/L ratios (p<0.001, 
Kruskal-Wallis test) were different in the 3 groups. The 
highest values (SUV >20, tumor to liver ratio >2,7) were 
observed in the 4 patients rated positive with increased 
uptake in all lesions. SUVpeak (9.8±2.5; p=0.01, T-test) 
and T/L ratios (1.4±0.3; p=0.02, T-test) were lower in the 
intermediate group and even lower (4.6±1.5 and 0.6±0.2, 
respectively; p<0.001 each, T-test) in the negative group.
Correlation of 68Ga-DOTATATE uptake and 
histopathology
In 19/21 patients, imaging results could be 
compared to immunohistological staining for SSTR2a 
and SSTR5 derived from biopsies of the primary tumor 
(n=15) or metastases (n=4). Regarding the histological 
evaluation of SSTR2a expression, 1/19 samples was rated 
“mild” (IRS 2), 2/19 “moderate” (both IRS 8) and 3/19 
“strongly” (one IRS 9, two IRS 12) positive, while 13/19 
were scored negative (2/13 with IRS 1 and 11/13 with IRS 
0). In contrast, 16/19 samples did not show any SSTR5 
expression (all IRS 0), 1/19 was mildly (IRS 2) and 2/19 
were moderately (both IRS 4) positive (Table 2).
SUVpeak as well as the T/L ratios were significantly 
correlated to the IRS score of SSTR2a expression 
(Spearman’s Rho: ρ=0.49 with p=0.03 and ρ=0.61 with 
p<0.01, respectively) but not to SSTR5 expression 
(Spearman’s Rho: ρ=0.31 with p=0.19 and ρ=0.27 with 
p=0.27, respectively) (Figure 2). In the Kruskal-Wallis 
test for differences in the groups of PET positivity, no 
significant differences were found for the SSTR5 IRS score 
(p=0.2). A difference for the SSTR2a IRS score (p<0.01) 
was attributable to a significantly higher score in the 4 
patients rated positive with increased uptake in all lesions; 
Figure 1: Example of SSTR-negative SCLC (patient #1). Maximum intensity projections as well as transaxial slices of FDG- 
and SSTR-PET/CT are displayed. The patient had multiple hypermetabolic lymph node, intrapulmonary and liver (arrows) lesions which 
showed intense FDG uptake. In contrast, 68Ga-DOTATATE PET demonstrated no relevant expression of somatostatin receptors with the 
liver metastases presenting as photopenic lesions (arrows).
Oncotarget20035www.impactjournals.com/oncotarget
no difference was observed between the “intermediate” and 
“negative” groups (p=0.96, Mann-Whitney test).
Interestingly, one patient (patient #17) had no 
detectable SSTR-expression in his biopsy sample taken 
from the primary tumor in the right bronchus consistent 
with SSTR-PET imaging, but showed high tracer binding 
in all metastases.
Prognostic value of 68Ga-DOTATATE-PET/CT 
and of SSTR2a-expression
Neither the SUV measured with PET/CT nor 
histological SSTR2a-expression had a prognostic value. 
Regression analysis (Spearman’s Rho) yielded SUVpeak vs. 
PFS: ρ=0.04 with p=0.87, SUVpeak vs. OS: ρ=0.09 with 
p=0.71, T/L vs. PFS: ρ=0.13 with p=0.58, T/L vs. OS: 
ρ=0.17 with p=0.46, SSTR2a IRS score vs. PFS: ρ=0.17 
with p=0.49, and SSTR2a IRS score vs. OS: ρ=0.05 with 
p=0.84.
PRRT
In total, 5/21 patients (4/4 of the positive group and 
1/6 of the intermediate group with the vast majority of 
lesions SSTR-positive) were considered eligible for PRRT. 
One patient opted for further chemotherapy, leading to a 
total of 4 SCLC patients undergoing 1, 1, 5 and 6 cycles 
of PRRT, respectively. Per cycle, 7.6±0.3 GBq of 177Lu-
DOTATATE (patients #2, #9 and #10) / -DOTATOC 
(patient #17) were administered, resulting in cumulative 
activities of 39.6, 7.4, 7.6, and 44.2 GBq of 177Lu, 
respectively. Treatment was well tolerated by all subjects 
without any changes in vital signs during therapy or 
significant therapy-related toxicity. Especially, no kidney 
failure or myelodysplastic syndrome was observed.
During follow-up, the patient undergoing 5 cycles 
of PRRT (patient #2) achieved partial response (Figure 3). 
PFS was 766 days and OS 907 days in patient #2. The 
patient with 6 cycles (patient #17) remained stable for 396 
Table 1: SUVpeak values, T/L ratios of the peak tumor to mean liver SUV and correlation of visual PET results and 
immunoreactive scores (IRS) for SSTR2a and SSTR5
Patient PET SUVpeak T/L SSTR2-IRS SSTR5-IRS
1 negative 6.0 0.4 0 0
2 positive 23.3 2.7 9 0
3 intermediate 9.2 1.8 1 0
4 negative 7.2 0.8 N/A N/A
5 intermediate 10.8 1.1 0 4
6 positive 32.5 4.8 8 0
7 intermediate 14.2 1.3 0 0
8 intermediate 9.1 1.4 8 2
9 positive 35.3 4.5 12 0
10 positive 20.5 2.7 12 2
11 negative 6.2 1.0 0 0
12 intermediate 8.5 1.6 0 0
13 negative 3.6 0.6 2 0
14 negative 4.8 0.8 0 0
15 negative 3.3 0.4 0 0
16 negative 5.4 0.8 0 0
17 intermediate 7.0 0.9 0 0
18 negative 3.9 0.4 1 0
19 negative 2.5 0.4 0 0
20 negative 2.8 0.8 1 0
21 negative 4.9 0.5 N/A N/A
For quantification of SSTR-positivity at PET, the categories “positive” (all tumor lesions PET-positive with 68Ga-
DOTATATE uptake > liver), “intermediate” (the majority of lesions positive) and “negative” (the majority of / all tumor 
lesions PET-negative) are used. The IRS score is given for histologically assessed SSTR2a/5 expression.
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Figure 2: Example of SSTR-directed PET imaging matching immunohistochemical quantification of receptor 
expression. Given are maximum intensity projections A, E. and immunohistochemical stainings of SCLC patients with high (Patient 
# 9, upper row; C) and low (patient #1, lower row; G) SSTR 2a expression. SSTR5 expression was low in both samples D, H. Positive 
controls for both SSTR2a and SSTR5 are shown in the inserts in panels G and H. Counterstaining was performed with hematoxylin B, F. 
Magnification: 200x B, F. and 400x C-H.
Figure 3: Example of SSTR-positive SCLC in a patient undergoing PRRT (patient #2). Given are maximum intensity 
projections as well as transaxial slices of SSTR-PET/CT in an SCLC patient (patient #2) prior to (left) and after (right) peptide receptor 
radionuclide therapy (PRRT). The patient had previously undergone 1st- (carboplatin/etoposid) and 2nd- (topotecan) line chemotherapy and 
presented with progressive disease. 68Ga-DOTATATE PET demonstrated intense expression of somatostatin receptors and SSTR-directed 
therapy was subsequently performed. After 4 cycles of PRRT, partial response could be recorded.
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days with a survival of 575 days. One of the two subjects 
with only 1 cycle of 177Lu-DOTATATE reported on an 
improvement of his overall performance status as well as 
of his pain (patient #9). This patient died from pneumonia 
prior to his second treatment cycle. The remaining patient 
(patient #10) did not benefit from radiopeptide therapy and 
deceased 53 days after PET imaging.
DISCUSSION
Management of SCLC remains a therapeutic 
challenge. Whereas cisplatin-based chemotherapeutic 
regimens are the mainstay of first-line therapy, a number 
of agents are offered for second-line treatment (usually 
employing the topoisomerase inhibitor topotecan). A 
standard third-line therapy has not been defined yet. PRRT 
has been investigated in this setting as an alternative for 
patients with high SSTR expression [9–11]. In our study, 
we could record a benefit from PRRT in 3 of 4 patients 
treated: One patient achieved partial response and another 
patient remained stable for more than a year. Given the 
median survival of <12 months in relapsed/refractory 
SCLC [12], both patients had a very encouraging outcome 
with an OS of 29 and 18 months, respectively. A third 
patient reported on improved performance status and pain 
relief after the first treatment cycle. Unfortunately, he died 
from pneumonia prior to the scheduled second PRRT.
Important prerequisites to SSTR-targeted therapy are 
a robust expression of as well as a specific binding to the 
target receptor. We could demonstrate a good correlation 
between imaging results and histopathological SSTR2a 
expression. However, only few patients qualified for PRRT 
by demonstrating higher receptor expression in tumors 
than in normal liver parenchyma. In our cohort, only 4 
subjects presented with all SCLC lesions SSTR-positive, 6 
presented with a mixture of mostly positive but also negative 
lesions. This finding highlights the phenomenon of tumor 
heterogeneity with variable features of both primary and 
metastatic cancer. Though a robust expression of SSTR has 
been described for SCLC biopsy specimens [5], receptor 
expression of the metastases can vary. Additionally, the 
dynamics of SSTR regulation under therapeutic pressure 
are unknown. Of note, the primary tumor biopsy sample 
of the patient undergoing the most cycles of PRRT was 
negative for SSTR expression. One might speculate that 
SCLC lesions with retained SSTR expression might still 
harbor more features of better differentiated neuroendocrine 
tumors and therefore be associated with a better prognosis. 
However, we did not observe any influence of receptor 
expression on progression-free or overall survival. SSTR-
directed PET/CT cannot serve as a non-invasive prognostic 
marker. Nevertheless, it can be used as a theranostic means 
for PRRT assessment.
Achieved tumor doses play an important role in 
treatment efficacy. In our study, all results were obtained 
after administration of standard activities of 177Lu. Recent 
in-house dosimetry studies have suggested the feasibility 
of individualized PRRT with safe administration of 
higher activities (data not published), possibly resulting 
in improved outcomes. This study has various limitations. 
It is retrospective and comprises a very limited number of 
observations with only 4 patients undergoing radiopeptide 
therapy. Biopsies were not always obtained in close 
proximity to PET imaging. However, it is the first report 
on an anti-tumor effect of SSTR-directed PRRT. Given its 
excellent tolerability, it can be considered in an otherwise 
very limited therapeutic scenario. Future research should 
try to optimize both PRRT procedures (individual 
dosimetry prior to therapy, shorter intervals between 
treatment cycles) as well as focus on new potential targets. 
One of those targets might be represented by chemokine 
receptor CXCR4, which has been described to be 
overexpressed in a vast number of malignancies, including 
SCLC [13, 14]. Proof-of-concept for visualization of 
CXCR4 expression by a radiolabelled PET ligand [15, 
16] has recently been demonstrated in SCLC patients 
[17]. As a compound allowing for labelling with various 
therapeutic α- and β-emitters is available [18], further 
evaluation of this theranostic approach is warranted.
In conclusion, SSTR-expression as detected by 
68Ga-DOTATATE and/or histology is not predictive of 
PFS or OS in patients with advanced SCLC. However, in 
patients exhibiting sufficient tracer uptake, PRRT might be 
considered an option given its low toxicity and the absence 
of effective alternative treatment options. Further research 
on novel therapeutic targets is warranted.
MATERIALS AND METHODS
Due to the retrospective nature of this study, 
our institutional review board waived the requirement 
for informed consent. Still, all patients gave written 
informed consent to receive SSTR-PET/CT imaging 
on a compassionate use basis for the purpose of PRRT 
assessment.
Patients
Between June 2011 and October 2013, 21 patients 
(12 males, 9 females, age, 41-74 y) with a history of 
extensive stage SCLC (n=18) or LCNEC (n=3) were 
enrolled. All but two patients had completed 1st- (cis-/
carboplatin/etoposide) and/or 2nd-line chemotherapy 
(topotecan, gemcitabine, ixoten) and showed progressive 
disease or tumor relapse on CT scans. Detailed patients’ 
characteristics are given in Table 2.
After PET/CT, patients were monitored until death 
with a median follow-up of 3 months (range 0–29 months). 
Progression-free (PFS) and overall survival (OS) were 
assessed by serial CT scans (every 3 months) according to 
Response Evaluation Criteria in Solid Tumors (RECIST) 
1.1 [19] and correlated to PET-derived parameters 
(SUVpeak, tumor to liver-ratio) as well as to biopsy-derived 
SSTR2a and SSTR5 expression.
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SSTR-PET/CT imaging
PET/CT was performed on an integrated scanner 
(Siemens Biograph mCT 64, Siemens, Knoxville, USA) 
consisting of a Lutetium oxyorthosilicate full-ring PET 
and a 64-slice spiral CT. 68Ga-DOTATATE (114 ± 34 
MBq) was injected intravenously. After a period of 40-60 
min, transmission and PET emission data were acquired as 
previously described [20].
All imaging tests were reviewed visually by two 
experienced nuclear medicine physicians (C.L., R.A.W.) 
who were blinded to clinical data. Patients were categorized 
according to SSTR-positivity as “positive” (all tumor 
lesions PET-positive with 68Ga-DOTATATE uptake > 
liver), “intermediate” (the majority of lesions positive) or 
“negative” (the majority of / all tumor lesions PET-negative).
For semi-quantitative analysis, peak standardized 
uptake values (SUVpeak) were calculated by assigning 
spherical volumes of interest of 1.5 cm diameter to 
the area of highest tracer uptake in tumororus tissue. 
In addition, a 5 cm spherical volume of interest was 
drawn to healthy tissue of the right lobe of the liver to 
determine the liver SUVmean, serving as reference for 
background activity. Tumor-to-liver ratios (T/L) were 
derived.
The 3 patient groups were tested by Kruskal-Wallis 
analysis for differences regarding the parameters age, 
SUVpeak, T/L ratio, PFS, OS, and the IRS scores for the 
histologically assessed SSTR2a/5 expression.
Immunhistochemical quantification of SSTR-
expression
In 19/21 patients, imaging results could be compared 
with histologic SSTR2a and SSTR5 expression of biopsy 
samples from primary tumors (n=15) or metastases (n=4).
Table 2: Patients’ characteristics
Patient sex Age (y) disease previous Tx Tx post PET PFS (d) OS (d)
1 m 74 LCNEC RTx none 2 5
2 f 74 SCLC RCTx (1st/2nd line) PRRT (5x) 766 907
3 m 64 SCLC None CTx 161 188
4 f 52 SCLC RCTx (1st/2nd line) CTx 69 93
5 f 56 SCLC CTx (1st line) CTx n/a 465
6 m 47 SCLC RCTx (1st/2nd line) CTx 51 66
7 m 54 SCLC RCTx (1st/2nd line) CTx 71 95
8 m 67 SCLC surgery, RCTx (1
st/2nd 
line) CTx 59 126
9 m 69 SCLC CTx (1st/2nd line) PRRT (1x) 115 118
10 m 66 SCLC CTx (1st/2nd line) PRRT (1x) 53 53
11 m 51 SCLC RCTx (1st/2nd line) CTx 26 38
12 f 65 SCLC RCTx (1st/2nd line) none 8 22
13 m 66 SCLC RCTx (1st line) none 3 3
14 f 52 LCNEC RCTx (1st line) CTx 308 432
15 m 78 LCNEC CTx (1st/2nd line) CTx 83 118
16 f 62 SCLC RCTx (1st/2nd line) CTx 324 434
17 m 48 SCLC RCTx (1st/2nd line) PRRT (6x) 396 575
18 m 51 SCLC RCTx (1st line) CTx 225 239
19 f 69 SCLC RCTx (1st/2nd line) RTx 8 27
20 f 59 SCLC RCTx (1st line) CTx 85 568
21 f 41 SCLC RCTx (1st line) CTx 63 95
CTx= chemotherapy; f= female; LCNEC= large cell neuroendocrine carcinoma; m= male; OS= overall survival; PFS= 
progression-free survival; PRRT= peptide receptor radionuclide therapy; RCTx= radio-chemotherapy; RTx= radiotherapy; 
SCLC= small cell lung cancer. The age of the patients is given in years, OFS and OS in days.
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Immunohistochemistry was carried out on 10% 
formalin fixed paraffin embedded tissue sections according 
to established protocols with a routine horseradish 
peroxidase-based labeling technique (ADVANCE; Dako, 
Hamburg, Germany) and diaminobenzidine as chromogen 
(DAB+; Dako) and an automated platform (Freedom 
EVO, Tecan, Crailsheim, Germany). Polyclonal antibodies 
against SSTR2a (1:500, RBK 046-05, Zytomed, Berlin, 
Germany) and SSTR5 (1:500, RBK 051-05, Zytomed, 
Berlin, Germany) were used. Samples from normal 
pancreatic tissue were used as positive control (islet cells). 
Dewaxed samples were pretreated with citrate buffer pH 
6.0 for 10 minutes (for SSTR2a staining) or respectively 
with the antigen retrieval agent TIRS-EDTA pH 9.0 for 10 
minutes in a high pressure cooker (for SSTR5 staining). 
All immunostained sections were counterstained for 3 
minutes with hematoxylin. The analysis of the stained 
sections was done semi-quantitatively by light-microscopy 
according to the immunoreactive score (IRS) by Remmele 
and Stegner [21]. The percentage of SSTR-positive cells 
was scored as follows: 0 (no positive cells), 1 (<10% 
positive cells), 2 (10-50% positive cells), 3 (>50-80% 
positive cells), 4 (>80% positive cells). Additionally, the 
intensity of staining was graded: 0 (no color reaction), 1 
(mild reaction), 2 (moderate reaction), 3 (intense reaction). 
Multiplication of both scores for a given sample yields 
the IRS classification: 0-1 (negative), 2-3 (mild), 4-8 
(moderate), 9-12 strongly positive.
PRRT
Peptide receptor radionuclide therapy (including 
renal protection) was performed according to the joint 
IAEA, EANM and SNMMI practical guidance [22]. In 
brief, all patients were hospitalized for a total of 3 days. 
PRRT with a median of 7.6 GBq (range, 7.2-8.5) of 
177Lu-DOTATATE/-TOC was intravenously administered 
over 30 minutes. Vital signs were documented during 
the infusion and within 7 days after administration. All 
patients were followed-up after PRRT including serial 
blood tests, kidney scintigraphy and SSTR-PET/CT. 
Treatment was performed with an interval of 8-12 weeks 
between each cycle.
Statistical analysis
Statistical analyses were performed using IBM 
SPSS (version 23.0). Data were analyzed with non-
parametric tests unless the Shapiro-Wilk test indicated 
compatibility with normal distribution. Quantitative 
values were expressed as mean ± standard deviation or 
median and range as appropriate. The tests used are 
reported together with the results. All statistical tests were 
performed two-sided and a p-value < 0.05 was considered 
to indicate statistical significance.
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